Myeloproliferative Neoplasms

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2024.

Idoroenyi Amanam, MD, discusses adverse effects associated with JAK inhibitors in myelofibrosis.

Guillermo Garcia-Manero, MD, discusses the investigation of luspatercept dose levels in patients with low-risk myelodysplastic syndrome who require red blood cell transfusions.

Areej El-Jawahri, MD, discusses a trial investigating a palliative oncology care model for patients with AML and MDS receiving nonintensive therapy.

Michael R. Grunwald, MD, discusses findings from a real-world observational study of risk factors related to disease progression in polycythemia vera.

Aaron Gerds, MD, discusses clinical implications and areas of unmet need for patients with low- or intermediate-1–risk myelofibrosis.

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

The National Comprehensive Cancer Network has issued category 1 and 2A recommendations for imetelstat as therapy for symptomatic anemia in patients with lower-risk MDS.

Justin M. Watts, MD, discusses the design and purpose of a phase 1 trial evaluating INCB057643 in myelofibrosis and other advanced myeloid neoplasms.

Tycel Phillips, MD, discusses the evolution of treatment for patients with myelodysplastic syndromes, highlighting the future of this treatment paradigm.

Justin M. Watts, MD, discusses phase 1 efficacy and safety data for the oral BET inhibitor INCB057643 in advanced myelofibrosis.

The FDA has placed a partial clinical hold on a trial evaluating seclidemstat plus azacitidine in myelodysplastic syndromes or chronic myelomonocytic leukemia.

Aaron Gerds, MD discusses updated efficacy findings from the prospective randomized phase 3 MANIFEST-2 trial.

Rebecca Klisovic, MD, discusses the early use of JAK inhibitors to treat younger patients with low-risk, newly diagnosed myelofibrosis.

Mikkael A. Sekeres, MD, discusses a subgroup analysis of treatment with imetelstat in patients with low-to intermediate-1–risk myelodysplastic syndrome.

Anthony M. Hunter, MD, discusses challenges associated with ruxolitinib-based toxicities in patients with myelofibrosis.

Aaron Gerds, MD, discusses progression data for patients with low- or intermediate-1–risk myelofibrosis in the MOST trial.

Mikkael A. Sekeres, MD, discusses the FDA approval of imetelstat for patients with low- to intermediate-1–risk MDS, highlighting data from a subanalysis.

Tycel Phillips, MD, highlights key takeaways in NHL, MDS, and myelofibrosis from an OncLive State of the Science Summit on hematology.

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

Anthony M. Hunter, MD, discusses the evolution of pathology in myelofibrosis based on outcomes from clinical trials.

Mikkael A. Sekeres, MD, discusses preliminary outcomes with oral azacitidine in lower-risk myelodysplastic syndromes, as reported in the ASTREON trial.

The Ministry of Health, Labour, and Welfare in Japan has approved momelotinib for use in patients with myelofibrosis.

This is safety and efficacy update on the MANIFEST-2 trial (NCT02158858), a global, randomized, double-blind, active-control, phase 3 study using pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.

Aaron Gerds, MD, discusses the clinical implications of outcomes with pelabresib plus ruxolitinib therapy in JAK inhibitor–naive myelofibrosis.

Patients with new or worsening anemia from their myelofibrosis did not experience lessened clinical benefit of ruxolitinib treatment.

Over a 4-year period, most patients with lower-risk myelofibrosis experienced disease progression, according to the prospective MOST study.

Justin M. Watts, MD, discusses the safety profile and tolerability of INCB057643 in patients with myelofibrosis.

Anthony Hunter, MD, discusses JAK inhibitor selection in myelofibrosis in the first line and beyond.

Mikkael A. Sekeres, MD, discusses the significance of the FDA approval of imetelstat for patients with lower-risk MDS and transfusion-dependent anemia.